Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ)

Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) — VMCI valuation read

Headline read on 000518.SZ: VMCI of 35/100 versus a Healthcare sector median of 50. The 15-point below-median position is what makes Jiangsu Sihuan Bioengineering Co., Ltd a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 000518.SZ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 000518.SZ: value (000518.SZ trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 3.0x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

000518.SZ rose 1.1% over the trailing 7 days, with a -12.1% read on a 30-day basis.